Laura Brege Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Laura Brege.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Laura Brege. Laura Brege is EVP and Chief Business Officer in ONYX PHARMACEUTICALS INC ($ONXX) and in ACADIA PHARMACEUTICALS INC ($ACAD) and Director in ACADIA PHARMACEUTICALS INC ($ACAD) and Director in DYNAVAX TECHNOLOGIES CORP ($DVAX) and Director in ANGIOTECH PHARMACEUTICALS INC ($ANPI) and Director in PORTOLA PHARMACEUTICALS INC ($PTLA) and Director in Pacira Pharmaceuticals, Inc. ($PCRX) and Director in ARATANA THERAPEUTICS, INC. ($PETX) and Director in Mirum Pharmaceuticals, Inc. ($MIRM).
Latest Insider Trading Transactions of Laura Brege
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ACAD, ANPI, PETX, DVAX, MIRM, ONXX, PCRX, PTLA
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jul 02 2020 | PTLA | PORTOLA PHARMACEUT ... | Brege Laura | Director | Option Exercise | D | 0.00 | 44,991 | 0 | 0 | |
| Jul 02 2020 | PTLA | PORTOLA PHARMACEUT ... | Brege Laura | Director | Option Exercise | D | 17.94 | 11,377 | 204,103 | 0 | |
| Jul 02 2020 | PTLA | PORTOLA PHARMACEUT ... | Brege Laura | Director | Sell | D | 18.00 | 7,281 | 131,058 | 0 | 7.3 K to 0 (-100.00 %) |
| Jul 02 2020 | PTLA | PORTOLA PHARMACEUT ... | Brege Laura | Director | Sell | D | 18.00 | 13,194 | 237,492 | 0 | 13.2 K to 0 (-100.00 %) |
| Jun 25 2020 | ACAD | ACADIA PHARMACEUTI ... | Brege Laura | Director | Option Exercise | A | 0.00 | 3,059 | 0 | 3,059 | |
| Jun 25 2020 | ACAD | ACADIA PHARMACEUTI ... | Brege Laura | Director | Option Exercise | A | 52.73 | 5,579 | 294,181 | 5,579 | |
| Jun 15 2020 | PTLA | PORTOLA PHARMACEUT ... | Brege Laura | Director | Option Exercise | A | 17.94 | 11,377 | 204,103 | 11,377 | |
| Jun 15 2020 | PTLA | PORTOLA PHARMACEUT ... | Brege Laura | Director | Grant | A | 0.00 | 7,281 | 0 | 20,475 | 13.2 K to 20.5 K (+55.18 %) |
| Jun 11 2020 | PCRX | Pacira BioSciences ... | Brege Laura | Director | Option Exercise | A | 47.65 | 8,027 | 382,487 | 8,027 | |
| Jun 11 2020 | PCRX | Pacira BioSciences ... | Brege Laura | Director | Grant | A | 0.00 | 1,260 | 0 | 7,921 | 6.7 K to 7.9 K (+18.92 %) |
| Jun 08 2020 | PCRX | Pacira BioSciences ... | Brege Laura | Director | Sell | S | 48.70 | 2,100 | 102,270 | 6,661 | 8.8 K to 6.7 K (-23.97 %) |
| Jan 08 2020 | ACAD | ACADIA PHARMACEUTI ... | Brege Laura | Director | Option Exercise | M | 1.75 | 10,000 | 17,500 | 0 | |
| Jan 08 2020 | ACAD | ACADIA PHARMACEUTI ... | Brege Laura | Director | Sell | S | 42.19 | 10,000 | 421,900 | 0 | 10 K to 0 (-100.00 %) |
| Jan 08 2020 | ACAD | ACADIA PHARMACEUTI ... | Brege Laura | Director | Buy | M | 1.75 | 10,000 | 17,500 | 10,000 | 0 to 10 K |
| Sep 12 2019 | MIRM | Mirum Pharmaceutic ... | Brege Laura | Director | Buy | P | 11.22 | 10,000 | 112,200 | 10,000 | 0 to 10 K |
| Jul 18 2019 | MIRM | Mirum Pharmaceutic ... | Brege Laura | Director | Option Exercise | A | 15.00 | 17,000 | 255,000 | 17,000 | |
| Jun 28 2019 | ACAD | ACADIA PHARMACEUTI ... | Brege Laura | Director | Option Exercise | A | 25.24 | 15,000 | 378,600 | 15,000 | |
| Jun 17 2019 | PTLA | PORTOLA PHARMACEUT ... | Brege Laura | Director | Option Exercise | A | 26.09 | 6,991 | 182,395 | 6,991 | |
| Jun 17 2019 | PTLA | PORTOLA PHARMACEUT ... | Brege Laura | Director | Grant | A | 0.00 | 4,194 | 0 | 13,194 | 9 K to 13.2 K (+46.60 %) |
| Jun 06 2019 | PCRX | Pacira BioSciences ... | Brege Laura | Director | Option Exercise | A | 43.54 | 8,437 | 367,347 | 8,437 | |
| Jun 06 2019 | PCRX | Pacira BioSciences ... | Brege Laura | Director | Grant | A | 0.00 | 4,134 | 0 | 8,761 | 4.6 K to 8.8 K (+89.35 %) |
| May 31 2019 | DVAX | DYNAVAX TECHNOLOGI ... | Brege Laura | Director | Option Exercise | A | 4.97 | 15,000 | 74,550 | 15,000 | |
| Jan 11 2019 | ACAD | ACADIA PHARMACEUTI ... | Brege Laura | Director | Option Exercise | M | 2.16 | 10,000 | 21,600 | 0 | |
| Jan 11 2019 | ACAD | ACADIA PHARMACEUTI ... | Brege Laura | Director | Sell | S | 20.00 | 10,000 | 200,041 | 0 | 10 K to 0 (-100.00 %) |
| Jan 11 2019 | ACAD | ACADIA PHARMACEUTI ... | Brege Laura | Director | Buy | M | 2.16 | 10,000 | 21,600 | 10,000 | 0 to 10 K |
| Jul 30 2018 | PETX | ARATANA THERAPEUTI ... | Brege Laura | Director | Option Exercise | A | 4.36 | 7,500 | 32,700 | 7,500 | |
| Jul 30 2018 | PETX | ARATANA THERAPEUTI ... | Brege Laura | Director | Grant | A | 0.00 | 4,500 | 0 | 13,500 | 9 K to 13.5 K (+50.00 %) |
| Jun 15 2018 | PCRX | Pacira Pharmaceuti ... | Brege Laura | Director | Option Exercise | A | 38.35 | 4,693 | 179,977 | 4,693 | |
| Jun 15 2018 | PCRX | Pacira Pharmaceuti ... | Brege Laura | Director | Grant | A | 0.00 | 782 | 0 | 4,627 | 3.8 K to 4.6 K (+20.34 %) |
| Jun 08 2018 | PTLA | PORTOLA PHARMACEUT ... | Brege Laura | Director | Option Exercise | A | 42.81 | 6,000 | 256,860 | 6,000 | |
| Jun 08 2018 | PTLA | PORTOLA PHARMACEUT ... | Brege Laura | Director | Grant | A | 0.00 | 3,000 | 0 | 9,000 | 6 K to 9 K (+50.00 %) |
| Jun 08 2018 | ACAD | ACADIA PHARMACEUTI ... | Brege Laura | Option Exercise | A | 17.52 | 15,000 | 262,800 | 15,000 | ||
| Jun 01 2018 | DVAX | DYNAVAX TECHNOLOGI ... | Brege Laura | Director | Option Exercise | A | 15.80 | 15,000 | 237,000 | 15,000 | |
| Jan 04 2018 | ACAD | ACADIA PHARMACEUTI ... | Brege Laura | Option Exercise | M | 8.49 | 10,000 | 84,900 | 0 | ||
| Jan 04 2018 | ACAD | ACADIA PHARMACEUTI ... | Brege Laura | Option Exercise | M | 8.06 | 15,000 | 120,900 | 0 | ||
| Jan 04 2018 | ACAD | ACADIA PHARMACEUTI ... | Brege Laura | Sell | S | 30.06 | 25,000 | 751,543 | 0 | 25 K to 0 (-100.00 %) | |
| Jan 04 2018 | ACAD | ACADIA PHARMACEUTI ... | Brege Laura | Buy | M | 8.49 | 10,000 | 84,900 | 25,000 | 15 K to 25 K (+66.67 %) | |
| Jan 04 2018 | ACAD | ACADIA PHARMACEUTI ... | Brege Laura | Buy | M | 8.06 | 15,000 | 120,900 | 15,000 | 0 to 15 K | |
| Jun 23 2017 | PETX | ARATANA THERAPEUTI ... | Brege Laura | Director | Option Exercise | A | 6.84 | 7,500 | 51,300 | 7,500 | |
| Jun 23 2017 | PETX | ARATANA THERAPEUTI ... | Brege Laura | Director | Grant | A | 0.00 | 4,500 | 0 | 9,000 | 4.5 K to 9 K (+100.00 %) |
| Jun 19 2017 | PTLA | PORTOLA PHARMACEUT ... | Brege Laura | Director | Option Exercise | A | 35.06 | 6,000 | 210,360 | 6,000 | |
| Jun 19 2017 | PTLA | PORTOLA PHARMACEUT ... | Brege Laura | Director | Grant | A | 0.00 | 3,000 | 0 | 3,000 | 0 to 3 K |
| Jun 16 2017 | PCRX | Pacira Pharmaceuti ... | Brege Laura | Director | Option Exercise | A | 44.20 | 2,714 | 119,959 | 2,714 | |
| Jun 16 2017 | PCRX | Pacira Pharmaceuti ... | Brege Laura | Director | Grant | A | 0.00 | 1,357 | 0 | 3,845 | 2.5 K to 3.8 K (+54.54 %) |
| Jun 14 2017 | ACAD | ACADIA PHARMACEUTI ... | Brege Laura | Option Exercise | A | 27.25 | 15,000 | 408,750 | 15,000 | ||
| Jun 02 2017 | DVAX | DYNAVAX TECHNOLOGI ... | Brege Laura | Director | Option Exercise | A | 5.90 | 7,500 | 44,250 | 7,500 | |
| Jun 28 2016 | PETX | ARATANA THERAPEUTI ... | Brege Laura | Director | Option Exercise | A | 6.12 | 7,500 | 45,900 | 7,500 | |
| Jun 28 2016 | PETX | ARATANA THERAPEUTI ... | Brege Laura | Director | Grant | A | 0.00 | 4,500 | 0 | 4,500 | 0 to 4.5 K |
| Jun 17 2016 | PCRX | Pacira Pharmaceuti ... | Brege Laura | Director | Option Exercise | A | 40.34 | 2,975 | 120,012 | 2,975 | |
| Jun 17 2016 | PCRX | Pacira Pharmaceuti ... | Brege Laura | Director | Grant | A | 0.00 | 1,488 | 0 | 2,488 | 1,000 to 2.5 K (+148.80 %) |
| Jun 10 2016 | ACAD | ACADIA PHARMACEUTI ... | Brege Laura | Option Exercise | A | 39.60 | 12,500 | 495,000 | 12,500 | ||
| Jun 08 2016 | PCRX | Pacira Pharmaceuti ... | Brege Laura | Director | Sell | S | 46.95 | 1,000 | 46,950 | 1,000 | 2 K to 1,000 (-50.00 %) |
| May 31 2016 | DVAX | DYNAVAX TECHNOLOGI ... | Brege Laura | Director | Option Exercise | A | 16.59 | 7,500 | 124,425 | 7,500 | |
| Oct 14 2015 | DVAX | DYNAVAX TECHNOLOGI ... | Brege Laura | Director | Option Exercise | A | 22.51 | 8,800 | 198,088 | 8,800 | |
| Jun 19 2015 | PETX | ARATANA THERAPEUTI ... | Brege Laura | Director | Option Exercise | A | 14.27 | 10,000 | 142,700 | 10,000 | |
| Jun 17 2015 | ACAD | ACADIA PHARMACEUTI ... | Brege Laura | Option Exercise | A | 39.06 | 12,500 | 488,250 | 12,500 | ||
| Jun 05 2015 | PCRX | Pacira Pharmaceuti ... | Brege Laura | Director | Option Exercise | A | 79.43 | 4,000 | 317,720 | 4,000 | |
| Jun 05 2015 | PCRX | Pacira Pharmaceuti ... | Brege Laura | Director | Grant | A | 0.00 | 2,000 | 0 | 2,000 | 0 to 2 K |
| May 28 2015 | DVAX | DYNAVAX TECHNOLOGI ... | Brege Laura | Director | Option Exercise | A | 22.36 | 1,875 | 41,925 | 1,875 | |
| Apr 19 2010 | ONXX | ONYX PHARMACEUTICA ... | Brege Laura | EVP and Chief Busin ... | Option Exercise | M | 15.44 | 12,500 | 193,000 | 100,000 | |
| Apr 19 2010 | ONXX | ONYX PHARMACEUTICA ... | Brege Laura | EVP and Chief Busin ... | Sell | S | 30.34 | 900 | 27,306 | 18,126 | 19 K to 18.1 K (-4.73 %) |
| Apr 19 2010 | ONXX | ONYX PHARMACEUTICA ... | Brege Laura | EVP and Chief Busin ... | Sell | S | 30.40 | 11,600 | 352,640 | 19,026 | 30.6 K to 19 K (-37.88 %) |
| Apr 19 2010 | ONXX | ONYX PHARMACEUTICA ... | Brege Laura | EVP and Chief Busin ... | Buy | M | 15.44 | 12,500 | 193,000 | 30,626 | 18.1 K to 30.6 K (+68.96 %) |
| Apr 02 2010 | ONXX | ONYX PHARMACEUTICA ... | Brege Laura | EVP and Chief Busin ... | Option Exercise | A | 30.28 | 56,000 | 1,695,680 | 56,000 | |
| Apr 02 2010 | ONXX | ONYX PHARMACEUTICA ... | Brege Laura | EVP and Chief Busin ... | Sell | S | 30.10 | 4,334 | 130,453 | 18,126 | 22.5 K to 18.1 K (-19.30 %) |
| Apr 02 2010 | ONXX | ONYX PHARMACEUTICA ... | Brege Laura | EVP and Chief Busin ... | Sell | S | 30.15 | 3,333 | 100,490 | 22,460 | 25.8 K to 22.5 K (-12.92 %) |
| Apr 02 2010 | ONXX | ONYX PHARMACEUTICA ... | Brege Laura | EVP and Chief Busin ... | Grant | A | 0.00 | 8,000 | 0 | 25,793 | 17.8 K to 25.8 K (+44.96 %) |
| Jan 20 2010 | ONXX | ONYX PHARMACEUTICA ... | Brege Laura | EVP and Chief Busin ... | Option Exercise | M | 15.44 | 12,500 | 193,000 | 112,500 | |
| Jan 20 2010 | ONXX | ONYX PHARMACEUTICA ... | Brege Laura | EVP and Chief Busin ... | Sell | S | 30.12 | 12,500 | 376,500 | 17,793 | 30.3 K to 17.8 K (-41.26 %) |
| Jan 20 2010 | ONXX | ONYX PHARMACEUTICA ... | Brege Laura | EVP and Chief Busin ... | Buy | M | 15.44 | 12,500 | 193,000 | 30,293 | 17.8 K to 30.3 K (+70.25 %) |
| Dec 04 2009 | ONXX | ONYX PHARMACEUTICA ... | Brege Laura | EVP and Chief Busin ... | Option Exercise | M | 15.44 | 12,500 | 193,000 | 125,000 | |
| Dec 04 2009 | ONXX | ONYX PHARMACEUTICA ... | Brege Laura | EVP and Chief Busin ... | Sell | S | 30.00 | 12,500 | 375,000 | 17,516 | 30 K to 17.5 K (-41.64 %) |
| Dec 04 2009 | ONXX | ONYX PHARMACEUTICA ... | Brege Laura | EVP and Chief Busin ... | Buy | M | 15.44 | 12,500 | 193,000 | 30,016 | 17.5 K to 30 K (+71.36 %) |
| Dec 14 2009 | ANPI | ANGIOTECH PHARMACE ... | Brege Laura | Director | Option Exercise | A | 1.35 | 12,500 | 16,875 | 42,500 | |
| Jul 24 2009 | ONXX | ONYX PHARMACEUTICA ... | Brege Laura | EVP and Chief Busin ... | Option Exercise | M | 15.44 | 25,000 | 386,000 | 137,500 | |
| Jul 24 2009 | ONXX | ONYX PHARMACEUTICA ... | Brege Laura | EVP and Chief Busin ... | Sell | S | 35.90 | 25,000 | 897,500 | 17,516 | 42.5 K to 17.5 K (-58.80 %) |
| Jul 24 2009 | ONXX | ONYX PHARMACEUTICA ... | Brege Laura | EVP and Chief Busin ... | Buy | M | 15.44 | 25,000 | 386,000 | 42,516 | 17.5 K to 42.5 K (+142.73 %) |
| Apr 02 2009 | ONXX | ONYX PHARMACEUTICA ... | Brege Laura | EVP and Chief Busin ... | Option Exercise | A | 28.55 | 49,000 | 1,398,950 | 49,000 | |
| Apr 02 2009 | ONXX | ONYX PHARMACEUTICA ... | Brege Laura | EVP and Chief Busin ... | Sell | S | 27.90 | 5,333 | 148,791 | 17,241 | 22.6 K to 17.2 K (-23.62 %) |
| Apr 02 2009 | ONXX | ONYX PHARMACEUTICA ... | Brege Laura | EVP and Chief Busin ... | Grant | A | 0.00 | 7,000 | 0 | 22,574 | 15.6 K to 22.6 K (+44.95 %) |
| Jun 11 2009 | ANPI | ANGIOTECH PHARMACE ... | Brege Laura | Director | Option Exercise | A | 2.06 | 5,000 | 10,300 | 30,000 | |
| Jan 20 2009 | ONXX | ONYX PHARMACEUTICA ... | Brege Laura | EVP and Chief Busin ... | Option Exercise | M | 15.44 | 12,500 | 193,000 | 162,500 | |
| Jan 20 2009 | ONXX | ONYX PHARMACEUTICA ... | Brege Laura | EVP and Chief Busin ... | Sell | S | 32.81 | 12,500 | 410,125 | 15,574 | 28.1 K to 15.6 K (-44.53 %) |
| Jan 20 2009 | ONXX | ONYX PHARMACEUTICA ... | Brege Laura | EVP and Chief Busin ... | Buy | M | 15.44 | 12,500 | 193,000 | 28,074 | 15.6 K to 28.1 K (+80.26 %) |
| Nov 10 2008 | ONXX | ONYX PHARMACEUTICA ... | Brege Laura | EVP and Chief Busin ... | Option Exercise | M | 15.44 | 12,500 | 193,000 | 175,000 | |
| Nov 10 2008 | ONXX | ONYX PHARMACEUTICA ... | Brege Laura | EVP and Chief Busin ... | Sell | S | 30.00 | 12,500 | 375,000 | 15,430 | 27.9 K to 15.4 K (-44.75 %) |
| Nov 10 2008 | ONXX | ONYX PHARMACEUTICA ... | Brege Laura | EVP and Chief Busin ... | Buy | M | 15.44 | 12,500 | 193,000 | 27,930 | 15.4 K to 27.9 K (+81.01 %) |
| Dec 10 2008 | ANPI | ANGIOTECH PHARMACE ... | Brege Laura | Director | Option Exercise | A | 0.16 | 5,000 | 800 | 25,000 | |
| Dec 10 2008 | ANPI | ANGIOTECH PHARMACE ... | Brege Laura | Director | Option Exercise | A | 0.16 | 5,000 | 800 | 20,000 | |
| Jul 17 2008 | ONXX | ONYX PHARMACEUTICA ... | Brege Laura | EVP and Chief Busin ... | Option Exercise | M | 15.44 | 12,500 | 193,000 | 187,500 | |
| Jul 17 2008 | ONXX | ONYX PHARMACEUTICA ... | Brege Laura | EVP and Chief Busin ... | Sell | S | 37.50 | 12,500 | 468,750 | 15,430 | 27.9 K to 15.4 K (-44.75 %) |
| Jul 17 2008 | ONXX | ONYX PHARMACEUTICA ... | Brege Laura | EVP and Chief Busin ... | Buy | M | 15.44 | 12,500 | 193,000 | 27,930 | 15.4 K to 27.9 K (+81.01 %) |
| Apr 16 2008 | ONXX | ONYX PHARMACEUTICA ... | Brege Laura | EVP and Chief Busin ... | Option Exercise | M | 15.44 | 12,500 | 193,000 | 200,000 | |
| Apr 16 2008 | ONXX | ONYX PHARMACEUTICA ... | Brege Laura | EVP and Chief Busin ... | Sell | S | 33.22 | 12,500 | 415,250 | 15,079 | 27.6 K to 15.1 K (-45.32 %) |
| Apr 16 2008 | ONXX | ONYX PHARMACEUTICA ... | Brege Laura | EVP and Chief Busin ... | Buy | M | 15.44 | 12,500 | 193,000 | 27,579 | 15.1 K to 27.6 K (+82.90 %) |
| Apr 02 2008 | ONXX | ONYX PHARMACEUTICA ... | Brege Laura | EVP and Chief Busin ... | Option Exercise | A | 29.03 | 20,000 | 580,600 | 20,000 | |
| Apr 02 2008 | ONXX | ONYX PHARMACEUTICA ... | Brege Laura | EVP and Chief Busin ... | Option Exercise | A | 29.03 | 42,000 | 1,219,260 | 42,000 | |
| Apr 02 2008 | ONXX | ONYX PHARMACEUTICA ... | Brege Laura | EVP and Chief Busin ... | Sell | S | 30.87 | 2,142 | 66,124 | 15,079 | 17.2 K to 15.1 K (-12.44 %) |
| Apr 02 2008 | ONXX | ONYX PHARMACEUTICA ... | Brege Laura | EVP and Chief Busin ... | Grant | A | 0.00 | 6,000 | 0 | 17,221 | 11.2 K to 17.2 K (+53.47 %) |
| Apr 02 2008 | ONXX | ONYX PHARMACEUTICA ... | Brege Laura | EVP and Chief Busin ... | Payment of Exercise | F | 29.03 | 1,192 | 34,604 | 11,221 | 12.4 K to 11.2 K (-9.60 %) |
| Jan 16 2008 | ONXX | ONYX PHARMACEUTICA ... | Brege Laura | EVP and Chief Busin ... | Option Exercise | M | 15.44 | 12,500 | 193,000 | 212,500 | |
| Jan 16 2008 | ONXX | ONYX PHARMACEUTICA ... | Brege Laura | EVP and Chief Busin ... | Sell | S | 50.89 | 12,500 | 636,125 | 12,413 | 24.9 K to 12.4 K (-50.17 %) |
| Jan 16 2008 | ONXX | ONYX PHARMACEUTICA ... | Brege Laura | EVP and Chief Busin ... | Buy | M | 15.44 | 12,500 | 193,000 | 24,913 | 12.4 K to 24.9 K (+100.70 %) |
| Aug 14 2007 | ONXX | ONYX PHARMACEUTICA ... | Brege Laura | EVP and Chief Busin ... | Option Exercise | M | 15.44 | 50,000 | 772,000 | 225,000 | |
| Aug 14 2007 | ONXX | ONYX PHARMACEUTICA ... | Brege Laura | EVP and Chief Busin ... | Sell | S | 31.25 | 19,608 | 612,750 | 11,512 | 31.1 K to 11.5 K (-63.01 %) |
| Aug 14 2007 | ONXX | ONYX PHARMACEUTICA ... | Brege Laura | EVP and Chief Busin ... | Sell | S | 31.26 | 800 | 25,008 | 31,120 | 31.9 K to 31.1 K (-2.51 %) |
| Aug 14 2007 | ONXX | ONYX PHARMACEUTICA ... | Brege Laura | EVP and Chief Busin ... | Sell | S | 31.27 | 2,200 | 68,794 | 31,920 | 34.1 K to 31.9 K (-6.45 %) |
| Aug 14 2007 | ONXX | ONYX PHARMACEUTICA ... | Brege Laura | EVP and Chief Busin ... | Sell | S | 31.28 | 200 | 6,255 | 34,120 | 34.3 K to 34.1 K (-0.58 %) |
| Aug 14 2007 | ONXX | ONYX PHARMACEUTICA ... | Brege Laura | EVP and Chief Busin ... | Sell | S | 31.28 | 200 | 6,256 | 34,320 | 34.5 K to 34.3 K (-0.58 %) |
| Aug 14 2007 | ONXX | ONYX PHARMACEUTICA ... | Brege Laura | EVP and Chief Busin ... | Sell | S | 31.29 | 100 | 3,129 | 34,520 | 34.6 K to 34.5 K (-0.29 %) |
| Aug 14 2007 | ONXX | ONYX PHARMACEUTICA ... | Brege Laura | EVP and Chief Busin ... | Sell | S | 31.30 | 1,500 | 46,950 | 34,620 | 36.1 K to 34.6 K (-4.15 %) |
| Aug 14 2007 | ONXX | ONYX PHARMACEUTICA ... | Brege Laura | EVP and Chief Busin ... | Sell | S | 31.31 | 100 | 3,131 | 36,120 | 36.2 K to 36.1 K (-0.28 %) |
| Aug 14 2007 | ONXX | ONYX PHARMACEUTICA ... | Brege Laura | EVP and Chief Busin ... | Sell | S | 31.37 | 1,900 | 59,603 | 36,220 | 38.1 K to 36.2 K (-4.98 %) |
| Aug 14 2007 | ONXX | ONYX PHARMACEUTICA ... | Brege Laura | EVP and Chief Busin ... | Sell | S | 31.38 | 100 | 3,138 | 38,120 | 38.2 K to 38.1 K (-0.26 %) |
| Aug 14 2007 | ONXX | ONYX PHARMACEUTICA ... | Brege Laura | EVP and Chief Busin ... | Sell | S | 31.40 | 3,500 | 109,900 | 38,220 | 41.7 K to 38.2 K (-8.39 %) |
| Aug 14 2007 | ONXX | ONYX PHARMACEUTICA ... | Brege Laura | EVP and Chief Busin ... | Sell | S | 31.49 | 400 | 12,596 | 41,720 | 42.1 K to 41.7 K (-0.95 %) |
| Aug 14 2007 | ONXX | ONYX PHARMACEUTICA ... | Brege Laura | EVP and Chief Busin ... | Sell | S | 31.51 | 100 | 3,151 | 42,120 | 42.2 K to 42.1 K (-0.24 %) |
| Aug 14 2007 | ONXX | ONYX PHARMACEUTICA ... | Brege Laura | EVP and Chief Busin ... | Sell | S | 31.50 | 11,092 | 349,398 | 42,220 | 53.3 K to 42.2 K (-20.81 %) |
| Aug 14 2007 | ONXX | ONYX PHARMACEUTICA ... | Brege Laura | EVP and Chief Busin ... | Sell | S | 31.53 | 2,600 | 81,978 | 53,312 | 55.9 K to 53.3 K (-4.65 %) |
| Aug 14 2007 | ONXX | ONYX PHARMACEUTICA ... | Brege Laura | EVP and Chief Busin ... | Sell | S | 31.56 | 300 | 9,468 | 55,912 | 56.2 K to 55.9 K (-0.53 %) |
| Aug 14 2007 | ONXX | ONYX PHARMACEUTICA ... | Brege Laura | EVP and Chief Busin ... | Sell | S | 31.58 | 200 | 6,316 | 56,212 | 56.4 K to 56.2 K (-0.35 %) |
| Aug 14 2007 | ONXX | ONYX PHARMACEUTICA ... | Brege Laura | EVP and Chief Busin ... | Sell | S | 31.57 | 400 | 12,628 | 56,412 | 56.8 K to 56.4 K (-0.70 %) |
| Aug 14 2007 | ONXX | ONYX PHARMACEUTICA ... | Brege Laura | EVP and Chief Busin ... | Sell | S | 31.61 | 3,700 | 116,957 | 56,812 | 60.5 K to 56.8 K (-6.11 %) |
| Aug 14 2007 | ONXX | ONYX PHARMACEUTICA ... | Brege Laura | EVP and Chief Busin ... | Sell | S | 31.64 | 1,000 | 31,640 | 60,512 | 61.5 K to 60.5 K (-1.63 %) |
| Aug 14 2007 | ONXX | ONYX PHARMACEUTICA ... | Brege Laura | EVP and Chief Busin ... | Buy | M | 15.44 | 50,000 | 772,000 | 61,512 | 11.5 K to 61.5 K (+434.33 %) |
| Apr 02 2007 | ONXX | ONYX PHARMACEUTICA ... | Brege Laura | EVP and Chief Busin ... | Option Exercise | A | 24.84 | 70,000 | 1,738,800 | 70,000 | |
| Apr 02 2007 | ONXX | ONYX PHARMACEUTICA ... | Brege Laura | EVP and Chief Busin ... | Grant | A | 0.00 | 10,000 | 0 | 11,512 | 1.5 K to 11.5 K (+661.38 %) |
| Jun 13 2006 | ONXX | ONYX PHARMACEUTICA ... | Brege Laura | EVP and Chief Busin ... | Option Exercise | A | 15.44 | 275,000 | 4,246,000 | 275,000 |
Page: 1